The Renal Project is a dialysis healthtech startup based in Mumbai, India, that runs small dialysis micro-centres for kidney patients, including in smaller cities.

This Startup Deep Dive explains what The Renal Project does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

The Renal Project in Brief

• What it is: The Renal Project is an Indian Dialysis micro-centre chain company based in Mumbai.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company sets up dialysis micro-centres with scalable capacity starting from 2 beds, often in collaboration with existing medical facilities, so dialysis is available where traditional centres are lacking.
• It is described as offering affordable hospital-based and home dialysis services, aimed at patients in Tier II and Tier III cities.
• December 2019: first seed funding from 100X.VC (reported).
• Funding: Rs 2.2 crore (about $300,000) in a pre-Series A round plus an earlier seed and an undisclosed 2024 pre-seed round (reported).

The Renal Project Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is The Renal Project?

The Renal Project operates in the Dialysis micro-centre chain space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to The Renal Project.

• The company sets up dialysis micro-centres with scalable capacity starting from 2 beds, often in collaboration with existing medical facilities, so dialysis is available where traditional centres are lacking.
• It is described as offering affordable hospital-based and home dialysis services, aimed at patients in Tier II and Tier III cities.

The Origin Story of The Renal Project

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Shashank Moddhia.
• One source credits Shashank Moddhia with launching the company in 2019; another source did not detail the founders, so founder attribution rests on limited reporting.
• The company raised its first seed funding from early-stage firm 100X.VC in December 2019 (reported).

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Dialysis micro-centre chain sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• December 2019: first seed funding from 100X.VC (reported).
• About 2020 to 2021: Rs 2.2 crore pre-Series A round from undisclosed international angel investors (reported).
• January 2024: JITO Angel Network led an undisclosed pre-seed round, with 100x VC, Gopi Latpate and Thapar Vision also participating (reported).
• One profile describes a network of over 40 locations across Maharashtra, Gujarat and Rajasthan (profile claim, not independently confirmed).

The Renal Project Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• December 2019: seed funding from 100X.VC (reported).
• Rs 2.2 crore (nearly $300,000) pre-Series A from international angels (reported).
• January 2024: undisclosed investment led by JITO Angel Network with 100x VC, Gopi Latpate and Thapar Vision (reported).

How Does The Renal Project Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Revenue comes from dialysis sessions delivered at micro-centres operated in partnership with existing medical facilities.

The Numbers: The Renal Project Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for The Renal Project were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for The Renal Project

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• The company targets dialysis access gaps in Tier II and Tier III cities where traditional dialysis centres are lacking.

Technology and Product at The Renal Project

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• The 2024 funds were earmarked for technology infrastructure and pipeline projects (reported).

Team and Culture at The Renal Project

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Shashank Moddhia is credited in one source as the founder.

The Renal Project Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of The Renal Project vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for The Renal Project

• The model depends on partnerships with host medical facilities, and public information on revenue and profitability is limited.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
• Thin margins: low-ticket services and heavy customer-acquisition spend can keep unit economics weak.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

The Renal Project Growth Outlook: What to Watch

• The 2024 funding was earmarked for technology infrastructure and pipeline projects.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether The Renal Project can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where The Renal Project Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for The Renal Project

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for The Renal Project.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from The Renal Project

Studying a company in the Dialysis micro-centre chain space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about The Renal Project.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate The Renal Project as a Startup

• Customer clarity: Can The Renal Project name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

The Renal Project is part of India’s growing Dialysis micro-centre chain ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

The Renal Project FAQs: Frequently Asked Questions

What is The Renal Project?

The Renal Project is a dialysis healthtech startup based in Mumbai, India, that runs small dialysis micro-centres for kidney patients, including in smaller cities. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded The Renal Project?

The Renal Project was founded by Shashank Moddhia, and the company reports a founding year of 2019.

How much funding has The Renal Project raised?

Rs 2.2 crore (about $300,000) in a pre-Series A round plus an earlier seed and an undisclosed 2024 pre-seed round (reported). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does The Renal Project make money?

The Renal Project earns revenue from its Dialysis micro-centre chain products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of The Renal Project?

Competitors of The Renal Project depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for The Renal Project?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Momentum Space — short profile of what is publicly known | Thinkerbell Labs — Thinkerbell’s Annie teaches braille without a teacher. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.